In the Press

According to the Trump administration, lowering prices on 15 Medicare drugs will save taxpayers billions

From AP News — Dec 2nd, 2025

Spencer Perlman, director of health care research at Veda Partners, says the Trump administration’s stronger outcomes in the latest round of Medicare drug price negotiations likely stem from the mix of drugs selected and lessons learned from the first negotiation cycle.

The administration announced that pharmaceutical companies agreed to reduce Medicare prices on 15 high-cost drugs—changes that could save taxpayers billions when they take effect in 2027. While exact savings for seniors will vary, Perlman noted the administration appears to have secured “meaningful price concessions,” showing the Medicare Drug Price Negotiation Program is functioning as intended.

This excerpt and any accompanying media (including audio, video, or images) are shared under the principles of fair use, for informational and archival purposes only. All rights remain with the original publisher.

Most Recent Appearances